Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
![Front Cover (V2)](https://www.ohe.org/wp-content/uploads/2019/07/Front-Cover-V2_0.jpg)
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.